ADV7103 + Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Distal Renal Tubular Acidosis
Conditions
Distal Renal Tubular Acidosis
Trial Timeline
Sep 20, 2021 → Dec 20, 2023
NCT ID
NCT03644706About ADV7103 + Placebo
ADV7103 + Placebo is a phase 3 stage product being developed by Advicenne for Distal Renal Tubular Acidosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03644706. Target conditions include Distal Renal Tubular Acidosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04147871 | Phase 2/3 | Withdrawn |
| NCT03644706 | Phase 3 | Terminated |
Competing Products
2 competing products in Distal Renal Tubular Acidosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AN2690, 2.5% + AN2690, 5% + AN2690, 7.5% + Vehicle | Pfizer | Phase 2 | 51 |
| AN2690, 2.5% + AN2690, 5% + AN2690, 7.5% + AN2690 Solution Vehicle | Pfizer | Phase 2 | 51 |